Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
REGULATORY Kobayashi Factory Inspected over Beni-Koji Health Issue
April 1, 2024
-
BUSINESS “Puberulic Acid” in Beni-Koji Supplements; Kobayashi Wants to Keep Healthcare Biz
April 1, 2024
-
REGULATORY LDP Lawmakers Call for Penalties against “Dump and Run Away” Generic Makers
March 29, 2024
-
REGULATORY Beni-Koji Issue: MHLW Requests Self-Inspections to Purchasers of Kobayashi’s Red Rice Yeast
March 29, 2024
-
BUSINESS Uber Eats Launches Delivery Service for Prescription Drugs in Japan
March 29, 2024
-
BUSINESS Taiho Bags Label Update for Lonsurf Combo Use with Bevacizumab
March 29, 2024
-
REGULATORY Label Revision Ordered for CAR-T Therapies to Add New Precaution
March 29, 2024
-
REGULATORY Japan PM Vows Early Kick Off of Off-Year Revision Debate at Chuikyo
March 29, 2024
-
REGULATORY Japan Diet Passes FY2024 Budget, Record Social Security Spending
March 29, 2024
-
BUSINESS BIKEN Files Nasal Flu Vaccine in Japan
March 29, 2024
-
BUSINESS Padcev/Keytruda Accepted for Chinese Review for 1st Line Bladder Cancer Use
March 29, 2024
-
BUSINESS Sumitomo-Sponsored Trial for Parkinson’s Cell Therapy to Commence in US
March 29, 2024
-
BUSINESS Parexel Helping Japan Address Drug Loss with “Ethnobridging” Studies, PI Still a Hurdle
March 29, 2024
-
REGULATORY MHLW Generic Panel Outlines Plan to Drive Industry Revamp within Specific Time Frame
March 28, 2024
-
BUSINESS Fuso Says Toray Jacked Up Damage Claim in Remitch Patent Suit
March 28, 2024
-
REGULATORY Japan’s HIV, AIDS Cases Rebound in 2023 after COVID
March 28, 2024
-
BUSINESS Sosei Group to Be Renamed “Nxera Pharma” from April
March 28, 2024
-
REGULATORY Japan Govt Launches Panel to Respond to Red Yeast Rice Issue
March 28, 2024
-
BUSINESS Abilify Maintena Gets EU Nod as 1st 2-Month Injectable for Schizophrenia
March 28, 2024
-
BUSINESS AstraZeneca’s Japan Sales Up 8.2% in 2023 Despite Nexium Patent Cliff
March 27, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…